Results 131 to 140 of about 9,578 (166)

Lessons from Ethiopian pharmaceutical regulation: a risk-based approach to overcome challenges and unlock opportunities. [PDF]

Front Med (Lausanne)
Hassen HK, Mekasha YT, Tegegne AA, Ozalp Y.   +3 more
europepmc   +1 more source

Research progress of DUB enzyme in breast cancer. [PDF]

Clin Exp Med
Tang W, Li N, Lai J.
europepmc   +1 more source

Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis <i>in vitro</i> and <i>in vivo</i>. [PDF]

Theranostics
Birappa G, Perumalsamy H, Hong SH, Gowda DAA, Chandrasekaran AP, Karapurkar JK, Rajkumar S, Balusamy SR, Jayachandran A, Baek KH, Lee J, Matam V, Kim WJ, Kim KS, Ramakrishna S, Suresh B.   +15 more
europepmc   +1 more source

Extending the Targets for Coronavirus Antivirals Beyond That of Approved Drugs: Insights From Preclinical Research. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs

Endocrine-Related Cancer, 2021
Cushing’s disease (CD) is a rare endocrine disorder caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor. Pasireotide is the only pituitary-targeted drug approved for adult patients. Nevertheless, many side effects are encountered and curative therapy is still challenging.
Donatella Treppiedi, Genesio Di Muro, Giusy Marra, Anna Maria Barbieri, Federica Mangili, Rosa Catalano, Andreea Serban, Emanuele Ferrante, Marco Locatelli, Andrea G Lania, Maura Arosio, Anna Spada, Erika Peverelli, Giovanna Mantovani   +13 more
openaire   +2 more sources

Design and Synthesis of KRAS ^G12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically

Journal of Medicinal Chemistry
Compared with positive control MRTX849, the synthesized compounds 7g, 7p, 7q, 7r, 7v, and 7y displayed stronger antiproliferative activities against H358 cells with IC50 values of < 1 nM (3D cell culture) and comparable inhibitory potency against KRASG12C.
Liangliang Tian, Qingxuan Han, Yanlong Qiao, Peng Chu, Lixue Chen   +4 more
openaire   +2 more sources

The deubiquitinating enzyme USP 8 promotes tyrosine kinase inhibitors resistance in chronic myeloid leukemia by stabilizing EIF 2 S 1 protein

The FEBS Journal
Tyrosine kinase inhibitors (TKIs), targeted therapeutic agents, have significantly improved survival outcomes in patients with chronic myeloid leukemia (CML). However, the emergence of drug resistance remains a challenge, with the underlying mechanisms still largely unknown.
Shan Zhang, Hurong Lai, Wanwan Bao, Caifeng Liao, Jian Li   +4 more
openaire   +1 more source